Hikma Pharmaceuticals PLC (HKMPY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hikma Pharmaceuticals PLC (HKMPY) trades at $41.03 with AI Score 45/100 (Grade C). Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products across various therapeutic areas. Market cap: $4.32B, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for HKMPY: HKMPY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HKMPY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HKMPY: the 1 perspectives are evenly split.
How is this calculated? →Hikma Pharmaceuticals PLC (HKMPY) Healthcare & Pipeline Overview
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company specializing in generic, branded, and injectable medications across diverse therapeutic areas. With a global presence spanning the US, MENA, and Europe, Hikma leverages its manufacturing capabilities and strategic partnerships to maintain a competitive edge in the specialty and generic drug market.
What Is the Investment Thesis for HKMPY?
Hikma Pharmaceuticals presents a compelling investment case based on its diversified revenue streams, strategic market positioning, and commitment to growth. The company’s focus on generic injectables, a high-barrier-to-entry market, provides a stable revenue base. With a P/E ratio of 10.7 and a dividend yield of 4.95%, Hikma offers value and income potential. Growth catalysts include expansion in emerging markets and successful product launches. However, investors should be aware of potential risks, including regulatory changes and competition from other generic manufacturers. Hikma's ability to navigate these challenges will be crucial for sustained growth and profitability.
Based on FMP financials and quantitative analysis
HKMPY Key Highlights
- Market capitalization of $4.32B reflects Hikma's established position in the pharmaceutical industry.
- Profit margin of 12.0% indicates efficient operations and effective cost management.
- Gross margin of 41.4% demonstrates Hikma's ability to maintain profitability despite pricing pressures in the generic drug market.
- Beta of 0.65 suggests lower volatility compared to the overall market, potentially offering stability in investment portfolios.
- Dividend yield of 4.95% provides an attractive income stream for investors.
Who Are HKMPY's Competitors?
HKMPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DNPUF Sumitomo Pharma Co., Ltd. | $10.50 | +11.58% | $4.71B | 59 |
| GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.20B | 43 |
| HLBBF H. Lundbeck A/S | $6.60 | +0.00% | $5.23B | 54 |
| HLUBF H. Lundbeck A/S | $5.50 | +0.00% | $5.84B | 54 |
| LVZPF Livzon Pharmaceutical Group Inc. | $4.35 | -16.67% | $5.05B | 49 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HKMPY's Key Strengths?
- Diversified product portfolio across generics, injectables, and branded products.
- Strong presence in key markets, including the United States, the Middle East, and North Africa.
- Established manufacturing capabilities and distribution network.
- Experienced management team with a track record of successful acquisitions.
What Are HKMPY's Weaknesses?
- Exposure to pricing pressures in the generic drug market.
- Dependence on key products and markets.
- Potential for regulatory challenges and compliance issues.
- Limited investment in innovative research and development.
What Could Drive HKMPY Stock Higher?
- Potential for new product approvals and launches in key therapeutic areas.
- Expansion in emerging markets, particularly in the MENA region.
- Strategic acquisitions and partnerships to expand product portfolio and geographic reach.
What Are the Key Risks for HKMPY?
- Pricing pressures in the generic drug market.
- Regulatory changes and compliance issues.
- Competition from other generic drug manufacturers.
- Currency fluctuations and economic downturns.
What Are the Growth Opportunities for HKMPY?
- Expansion in Emerging Markets: Hikma has a significant opportunity to expand its presence in emerging markets, particularly in the Middle East and North Africa (MENA) region. These markets are experiencing rapid growth in healthcare spending, driven by increasing populations and rising incomes. By leveraging its existing infrastructure and partnerships, Hikma can capitalize on this growth and increase its market share. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- New Product Launches: Hikma's pipeline of generic and branded products represents a significant growth opportunity. Successful launches of new medications can drive revenue growth and increase profitability. The company's focus on specialty generics and injectables, which often have higher barriers to entry, can provide a competitive advantage. Upcoming product launches in key therapeutic areas, such as oncology and cardiovascular disease, are expected to contribute to revenue growth in the near term.
- Strategic Acquisitions: Hikma can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquisitions can provide access to new markets, technologies, and expertise, accelerating growth and enhancing competitiveness. The company has a track record of successful acquisitions, and further strategic deals could drive significant value creation in the coming years.
- Biosimilar Development: The increasing demand for biosimilars, driven by the expiration of patents on blockbuster biologic drugs, presents a significant growth opportunity for Hikma. Biosimilars offer a lower-cost alternative to branded biologics, and Hikma can leverage its expertise in generic drug development to capitalize on this trend. Investment in biosimilar development and manufacturing capabilities can drive long-term growth and profitability.
- Partnerships and Collaborations: Hikma can pursue partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to accelerate innovation, expand its product portfolio, and access new markets. Collaborations can provide access to new technologies, expertise, and distribution channels, enhancing competitiveness and driving growth. Strategic partnerships can also help mitigate risks and reduce development costs.
What Opportunities Does HKMPY Have?
- Expansion in emerging markets with growing healthcare spending.
- New product launches and pipeline development.
- Strategic acquisitions and partnerships.
- Increasing demand for biosimilars.
What Threats Does HKMPY Face?
- Competition from other generic drug manufacturers.
- Patent expirations and loss of exclusivity.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and currency fluctuations.
What Are HKMPY's Competitive Advantages?
- Manufacturing capabilities: Hikma has established manufacturing facilities that allow it to produce a wide range of pharmaceutical products.
- Established distribution network: The company has a strong distribution network in key markets, including the United States, the Middle East, and North Africa.
- Product portfolio: Hikma offers a diversified portfolio of generic, branded, and in-licensed pharmaceutical products.
- Regulatory expertise: The company has experience navigating complex regulatory requirements in various markets.
What Does HKMPY Do?
Founded in 1978 and headquartered in London, Hikma Pharmaceuticals PLC has evolved into a significant player in the global pharmaceutical industry. The company develops, manufactures, and markets a broad portfolio of pharmaceutical products, including generic, branded, and in-licensed medications. Hikma operates through three key segments: Injectables, Generics, and Branded. The Injectables segment focuses on providing generic injectable products primarily for hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment provides branded generics and in-licensed products to retail and hospital markets. Hikma's products cover a wide range of therapeutic areas, including anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. The company has a strong presence in the United States, the Middle East, North Africa, Europe, and the United Kingdom, allowing it to serve diverse patient populations and healthcare systems. Hikma's commitment to quality, innovation, and strategic partnerships has enabled it to maintain a competitive position in the pharmaceutical market.
What Products and Services Does HKMPY Offer?
- Develops and manufactures generic pharmaceutical products.
- Markets and sells branded pharmaceutical products.
- Offers injectable medications primarily for hospital use.
- Provides oral and non-injectable generic products for retail markets.
- In-licenses pharmaceutical products for distribution.
- Operates in various therapeutic areas, including cardiovascular, oncology, and diabetes.
- Serves markets in the United States, Middle East, North Africa, Europe, and the United Kingdom.
How Does HKMPY Make Money?
- Develops and manufactures generic and branded pharmaceutical products.
- Markets and sells products through three segments: Injectables, Generics, and Branded.
- Generates revenue through sales of pharmaceutical products to hospitals, retail pharmacies, and other healthcare providers.
What Industry Does HKMPY Operate In?
Hikma Pharmaceuticals operates within the global pharmaceutical industry, which is characterized by increasing demand for generic medications, driven by cost containment measures and patent expirations. The market is highly competitive, with companies like DNPUF (Daiichi Sankyo) and GZPHF (Guangzhou Pharmaceutical) vying for market share. Hikma's focus on specialty generics and injectables allows it to differentiate itself in this competitive landscape. The industry is also subject to stringent regulatory requirements and pricing pressures, requiring companies to maintain operational efficiency and adapt to changing market dynamics.
Who Are HKMPY's Key Customers?
- Hospitals and healthcare facilities (for injectable medications).
- Retail pharmacies (for oral and non-injectable generic products).
- Patients (through prescriptions and over-the-counter medications).
- Wholesalers and distributors (who supply medications to pharmacies and hospitals).
ROE 16%Key Financial Metrics
Return on equity for Hikma Pharmaceuticals PLC stands at 15.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. HKMPY trades at a trailing price-to-earnings ratio of 10.75, below the Healthcare sector average of ~23x. Its free cash flow yield is 4.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.2%, the inverse of the P/E and a quick read on earnings relative to price.
How Hikma Pharmaceuticals PLC Is Valued
Hikma Pharmaceuticals PLC carries a market capitalization of $4.32B, placing it in the mid-cap category. Relative to its peer group, HKMPY's quantitative score of 45/100 is roughly in line with the peer average of 52/100.
F-Score 7/9Financial Health
Hikma Pharmaceuticals PLC's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.58 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Hikma Pharmaceuticals PLC revenue of about $3.47B for fiscal 2026, with EPS near $0.00. The estimate reflects 9 contributing analysts.
HKMPY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Hikma's growth potential, indicating that leadership believes in the company's future.
- Community sentiment has shifted positively, with discussions highlighting the strength of Hikma's pipeline and product offerings.
- Analysts have noted the company's strategic partnerships that could enhance market reach and profitability.
- The pharmaceutical sector's resilience in uncertain economic times has positioned Hikma favorably among investors seeking stability.
Bear Case
- Concerns over regulatory changes in the pharmaceutical industry have led to increased scrutiny on companies like Hikma, creating uncertainty.
- Recent community discussions reflect skepticism regarding Hikma's ability to compete with larger players in the market.
- Insider selling activity has raised red flags among some investors, suggesting potential lack of confidence from key stakeholders.
- Market perception is clouded by broader economic challenges that could impact pharmaceutical sales and growth projections.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
HKMPY Latest News
-
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
prnewswire.com · Jun 4, 2026
-
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
globenewswire.com · Jun 1, 2026
HKMPY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HKMPY.
Price Targets
Wall Street price target analysis for HKMPY.
HKMPY MoonshotScore
What does this score mean?
The MoonshotScore rates HKMPY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Said Samih Taleb Darwazah
CEO
Said Samih Taleb Darwazah is the Chief Executive Officer of Hikma Pharmaceuticals PLC. His career spans several decades in the pharmaceutical industry, marked by leadership roles and a deep understanding of global healthcare markets. He has been instrumental in driving Hikma's growth and expansion, particularly in the MENA region and the United States. His expertise includes strategic planning, business development, and operational management. He is responsible for overseeing the company's overall strategy and performance.
Track Record: Under Said Darwazah's leadership, Hikma has achieved significant milestones, including expanding its product portfolio, entering new markets, and strengthening its manufacturing capabilities. He has overseen several strategic acquisitions that have enhanced Hikma's competitive position. His focus on innovation and operational efficiency has contributed to the company's sustained growth and profitability. He has also navigated complex regulatory challenges and pricing pressures in the pharmaceutical industry.
Hikma Pharmaceuticals PLC ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. HKMPY is an ADR, meaning it allows U.S. investors to invest in Hikma Pharmaceuticals PLC without directly dealing with the London Stock Exchange (LSE) where the ordinary shares (HKMP) are listed. The ADR represents a specific number of ordinary shares.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: HKMP
HKMPY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure, may not meet minimum listing standards, and are generally considered to be higher risk investments compared to companies listed on major exchanges like the NYSE or NASDAQ. OTC Other stocks may have limited trading volume and wider bid-ask spreads, making them more difficult to trade.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower liquidity and wider bid-ask spreads.
- Potential for price volatility and manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings against the company.
- Established presence in the pharmaceutical industry.
- Global operations and diversified product portfolio.
- Compliance with regulatory requirements in key markets.
- Experienced management team.
- Positive analyst ratings (if available).
Hikma Pharmaceuticals PLC Healthcare Stock: Key Questions Answered
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC is a global pharmaceutical company that develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. Its products cover various therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, and respiratory. Hikma serves markets in the United States, the Middle East, North Africa, Europe, and the United Kingdom, providing essential medications to patients and healthcare providers.
What are the main risks for HKMPY?
Hikma Pharmaceuticals PLC faces several risks, including pricing pressures in the generic drug market, competition from other generic drug manufacturers, regulatory changes and compliance issues, and currency fluctuations. The company's dependence on key products and markets also poses a risk. Investors should carefully consider these risks before investing in HKMPY stock. Hikma's ability to mitigate these risks will be crucial for sustained growth and profitability.
What are the key factors to evaluate for HKMPY?
Hikma Pharmaceuticals PLC (HKMPY) holds an AI score of 45/100 (low). P/E: 10.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does HKMPY data refresh on this page?
HKMPY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HKMPY's recent stock price performance?
Hikma Pharmaceuticals PLC (HKMPY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across generics, injectables, and branded products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HKMPY overvalued or undervalued right now?
Hikma Pharmaceuticals PLC (HKMPY) trades at 10.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HKMPY?
Before investing in Hikma Pharmaceuticals PLC (HKMPY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding HKMPY to a portfolio?
Key strength of Hikma Pharmaceuticals PLC (HKMPY): Diversified product portfolio across generics, injectables, and branded products. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for HKMPY, which could provide additional insights.
- OTC market data may be less reliable than data from major exchanges.